of amplification facilitator. Taken together, these data show that only the addition of 0.04% BSA would allow a quantitative follow-up of the MRD. In the case of addition of 0.2% of BSA, there was a decrease in ABL CN (Figure 2a ) and an increase in TEL-AML1 CN (Figure 2b ) forbidding any accurate quantification. Actually, this effect was due to a variation of cycle threshold (C t ) value for the cDNA measurements with no modification of the plasmid standard curve (not shown).
In chronic myeloid leukaemia (CML), the fusion gene BCR-ABL is created by the characteristic t(9;22) translocation. The fusion gene product is the p210 BCR-ABL protein, which has enhanced tyrosine kinase activity in comparison with wild-type ABL. The amino-acid sequences around the BCR-ABL fusion junction are novel to the immune system. Several groups have shown that peptides derived from the junction may elicit both CD8 þ cytotoxic T-cell (CTL) and CD4 þ proliferative T-cell responses in normal subjects and also elicit CTL responses in CML patients. It appears likely that BCR-ABL junctional peptides are endogenously presented in CML patients. CML cells may themselves present peptides derived from the BCR-ABL junction on the cell surface in association with HLA class I molecules. 1 Dendritic cells (DC) are potent antigen-presenting cells that have evolved to monitor the environment, detect pathogens and trigger T-cell responses. Several studies have established that DC in CML are derived from the leukaemic clone. DC from all 19 patients examined for BCR-ABL fusion by Fluorescent in situ hybridisation (FISH) in three studies were at least 73% FISH positive. [2] [3] [4] These patients had active disease at the time of study, mostly in first chronic phase. The DC used in each of these studies were derived from PB mononuclear cells, which in some cases were first selected for monocytes.
DC function may be abnormal in CML. CML cells have been shown to use a classic MHC class II antigen-processing pathway to present nonleukaemic antigens to CD4 þ T cells. 5 In comparison to normal DC, DC derived from CML patients demonstrate differences in cytoskeletal organisation and impaired migration, and a reduced capacity to capture and present nonleukaemic antigen. 6 CML-derived DC were less effective than normal DC in eliciting an allogeneic mixed lymphocyte reaction. 7 DC derived from CML patients have been shown to process and present endogenous BCR-ABL to CD4 þ T cells. 2 Imatinib (trade name Glivec or Gleevec) is an inhibitor of the tyrosine kinase activity of ABL and BCR-ABL. Its introduction into the therapy of CML has produced some remarkable results, especially if used soon after initial diagnosis. In a recent report, almost all newly diagnosed cases receiving imatinib achieved complete haematological responses, and 76% of cases achieved complete cytogenetic remissions (CCR), compared with 14% of patients receiving interferon-a (IFN-a) and cytarabine. 8 It is not yet known whether imatinib may improve survival in CML, in comparison to IFN-a and cytarabine, although the high incidence of CCR, coupled with the demonstration in several earlier studies of IFN-a that achieving CCR correlates with superior survival, is encouraging. However, the concomitant removal of cells capable of presenting endogenous BCR-ABL to the immune system might adversely affect an existing immune response to BCR-ABL. We therefore decided to look at DC clonality in patients who achieved an imatinib-induced CCR.
A total of 17 patients with Philadelphia (Ph) chromosome positive CML were included in the study ( Table 1 ). The main study population comprised eight patients known to be in CCR following imatinib treatment at a dose of 400-600 mg daily. Nine additional patients were included for comparison. DC were generated from CD14 þ monocytes purified by using MiniMACS (Miltenyi Biotec, Surrey, UK) in RPMI1640 medium supplemented with 10% (v/v) foetal calf serum containing recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF; Sigma-Aldrich Ltd, Dorset, and PeproTech EC Ltd, London, UK) 1000 U/ml and Interleukin-4 (IL-4; Sigma-Aldrich Ltd, Dorset, UK) 500 U/ml for 7 days in 12-well plates. Tumour necrosis factor-a (TNF-a; Sigma-Aldrich Ltd, Dorset, UK) was added at a concentration of 1000 U/ml to mature the DC. Flow cytometric analysis of cell surface antigens of DC preparations showed that compared to the parent populations, CD1a, CD80, CD86 and HLA-DR were increased in all cases, except that CD86 was not upregulated in DC from one blast crisis phase patient. CD14 was downregulated in all cases. The mean fluorescence of all isotype controls was within the first decade. In all DC preparations, at least 94% of cells were CD80 and/or CD86 positive. BCR-ABL mRNA expression of peripheral blood white cell and DC preparations was initially assessed by reverse transcription-polymerase chain reaction (PCR). If this was negative, nested PCR was then carried out. Sensitivity of nested PCR was one K562 cell in 10 7 CV727 cells. As shown in Table 1 , DC preparations from all eight cases treated with imatinib and in CCR were BCR-ABL negative by nested PCR even though in six of these eight cases the parallel WBC remained BCR-ABL positive by nested PCR. In four of these eight cases, material was available to carry out FISH on the DC preparations and was negative on all four cases (between 5 Â 10 4 and 5 Â 10 5 cells were tested by FISH). In contrast, DC preparations from all imatinib-treated cases not in CCR and all patients treated by other means (including one case in CCR treated with IFN only) were BCR-ABL positive. BCR-ABL mRNA expression was also quantified using a LightCycler (Roche Diagnostics Ltd, East Sussex, UK) as previously described 9 for chronic phase cases in whom DC BCR-ABL expression remained positive. Although the amount of BCR-ABL expression is variable between patients, in each case the DC BCR-ABL expression is consistently lower than the corresponding expression in WBC. This contrast is seen even though the WBC population may have been 'diluted' to varying degrees by Ph negative lymphocytes. This may be because DC are known to turn over rapidly, as exemplified by studies on DC reconstitution after stem cell transplantation. 10 Imatinib may therefore produce a proportionally greater inhibitory effect on DC due to their rapid turnover.
In our present study DC were generated from peripheral blood monocytes. It was shown that DC are BCR-ABL negative in patients who enter CCR on imatinib. The FISH data show that they are normal DC, rather than Ph þ DC, which are not transcribing BCR-ABL. It is unlikely that the DC enrichment steps might have preferentially selected DC from normal DC precursors, since there is evidence that DC preparation in CML may preferentially select for Ph þ rather than normal DC.
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Taken together with previous studies on DC clonality in florid CML, the present data suggest that normal DC may replace BCR-ABL positive DC in CML chronic phase patients achieving CCR on imatinib. A recently published study also showed that normal plasmacytoid DC number and secretion of IFN-a could be restored in imatinib responding CML patients. 12 This may be advantageous, since leukaemic DC may not process antigen normally in CML. 6 However, disappearance of the BCR-ABL positive DC population may be disadvantageous, since DC can then no longer present leukaemia-specific endogenously derived BCR-ABL peptides to the immune system. Further studies are required to define whether imatinib treatment may also modify BCR-ABL directed T-cell responses. 
